Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma

Maria Lapuente

Dawn Conway

Laura S. Wood

Kiran Kehoe

Andrea Carroll Bullock

Geeta Devgan

Kathleen D. Burns

avelumab first-line maintenance, bladder cancer, immune-related adverse events
CJON 2023, 27(1), 71-80. DOI: 10.1188/23.CJON.71-80

Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.

Objectives: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.

Methods: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.

Findings: Oncology nurses can provide comprehensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct administration, and promptly recognizing and managing immune-related adverse events.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.